GSK3B and Cognitive impairment: In transgenic models, overexpressing or chronically activating GSK3β induces tau pathology and cognitive deficits, whereas pharmacologically inhibiting GSK3β prevents those changes (Arciniegas Ruiz and Eldar-Finkelman, 2022).